Thomas Fredick Wierzba, PhD, MS, MPH
- Professor, Infectious Diseases
Thomas Fredick Wierzba, PhD, MS, MPH
- Positions
- Professor, Infectious Diseases
- Professor, Epidemiology and Prevention
- Departments and Affiliations
- Infectious Diseases
- Epidemiology and Prevention
- Office of Global Health
- Center for Vaccines at the Extremes of Aging
Research
- Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference. Barry E, Cassels F, Riddle M, Walker R, Wierzba T. Vaccine. 2019 08; 37(34):4768-4774.
- Implications and measurement of herd protection (indirect effects) for enteric vaccine development. Wierzba TF. Vaccine. 2019 08; 37(34):4775-4777.
- Potential impact and cost-effectiveness of future ETEC and Shigella vaccines in 79 low- and lower middle-income countries. Anderson JD, Bagamian KH, Muhib F, Baral R, Laytner LA, Amaya M, Wierzba T, Rheingans R. . 2019 Aug; 2:100024.
- A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children. Raqib R, Sarker P, Zaman K, Alam NH, Wierzba TF, Maier N, Talukder K, Baqui AH, Suvarnapunya AE, Qadri F, Walker RI, Fix A, Venkatesan MM. Hum Vaccin Immunother. 2019; 15(6):1326-1337.
- Burden of enterotoxigenic Escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis. Anderson JD, Bagamian KH, Muhib F, Amaya MP, Laytner LA, Wierzba T, Rheingans R. Lancet Glob Health. 2019 03; 7(3):e321-e330.